WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
News & Events
Maps & Locations
PATIENT AND VISITOR INFORMATION
PREVENTION AND SCREENING
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Content Block Control
RETURN TO SEARCH RESULTS
A Phase II Evaluation of SU11248 (Sunitinib Malate) In the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
The purpose of this study is to find out if SU11248 (sunitinib malate) works in treating your type of cancer and to find out what side effects are caused by treatment with this drug. Sunitinib has been approved by the Food and Drug Administration (FDA) for the treatment of a type of stomach cancer called gastrointestinal stromal tumor (called GIST) and kidney cancer (called renal cell carcinoma). It is an experimental drug not approved by the FDA for the treatment of ovarian cancer.
Sunitinib blocks a very important mechanism that controls the growth of cancer cells, including ovarian cancer. It prevents VEGF (the vascular endothelial growth factor), a hormone that causes blood vessel growth to tissues, from working. Sunitinib has been shown to work in temporarily stopping or slowing tumor growth in patients with other types of cancer. This clinical trial will determine whether Sunitinib is active in treating patients with clear cell ovarian cancer that has re-grown or not responded after prior treatment.
In addition to the treatment part of this study, the researchers plan to test samples of your tumor (if available from a previous surgery or biopsy) and your blood. The purpose of this research is to determine if this testing can be used in the future to determine which patients may respond to treatment or have a good prognosis.
(Links will take you off this web site)
Internal Protocol Documents (requires Siteman administrative database password)
© 2009 All rights reserved